SOS1 and familial pancreatic carcinoma: Through unbiased drug screening experiments in the context of pancreatic cancer, we observed that KRASG12C inhibitors combine favorably with inhibitors of the tyrosine phosphatase SHP2, a broad‐acting kinase inhibitor, and inhibitors of the guanine nucleotide exchange factor SOS1.